Physicians' experience and opinion on contraindications to allergen immunotherapy: The CONSIT survey |
| |
| Authors: | Pablo Rodríguez del Rio Constantinos Pitsios Marina Tsoumani Oliver Pfaar Giannis Paraskevopoulos Radoslaw Gawlik Erkka Valovirta Desirée Larenas-Linnemann Pascal Demoly Moises A. Calderón |
| |
| Affiliation: | 1. Allergy Section, Children''s University Hospital “Niño Jesús”, Madrid, Spain;2. Medical School, University of Cyprus, Nicosia, Cyprus;3. Centre for Respiratory Medicine and Allergy, University Hospital of South Manchester and Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom;4. Department of Otorhinolaryngology, Head and Neck Surgery, Universitätsmedizin Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany;6. Center for Rhinology and Allergology, Wiesbaden, Germany;5. Allergy Outpatient Clinic, 401 General Military Hospital of Athens, Athens, Greece;7. Terveystalo Turku, Allergy Clinic, University of Turku, Turku, Finland;11. Hospital Medica Sur, Mexico DF, Mexico;12. Département de Pneumologie et Addictologie, Hôpital Arnaud de Villeneuve, University Hospital of Montpellier; Sorbonne Universités, UPMC Paris 06, UMR-S 1136, IPLESP, Equipe EPAR, 75013, Paris, France;8. Section of Allergy and Clinical Immunology, Imperial College London, National Heart and Lung Institute and Royal Brompton Hospital NSH, London, United Kingdom |
| |
| Abstract: | BackgroundAllergen immunotherapy (AIT) is the only disease-modifying treatment in allergy but several contraindications limit its use.ObjectiveTo collect the outcome of using AIT in theoretically contraindicated situations in real patients in the Contraindications to Specific ImmunoTherapy (CONSIT) survey.MethodsThe CONSIT is an electronic European Academy of Allergy and Clinical Immunology survey conducted to gather the safety outcomes of patients undergoing subcutaneous, sublingual, or venom AIT and the opinions of physicians on each of 17 selected conditions: children younger than 5 years; starting AIT during pregnancy; controlled severe asthma; arrhythmias; coronary disease; cancer; autoimmune disease; bone marrow and solid organ transplantation; human immunodeficiency virus and acquired immunodeficiency syndrome; previous anaphylaxis during AIT; use of β-blockers, angiotensin-converting inhibitors, cyclosporine, and methotrexate; and inability to communicate. Safety using AIT was reported in a 3-point scale: 1, “no problems”; 2, “minor problems” (requiring only dose modifications); and 3, “major problems” (AIT not tolerated). Each physician was asked about the degree of contraindication that each condition should have: no contraindication (score 1), relative contraindication (score 2), or absolute contraindication (score 3).ResultsFive hundred twenty physicians (75% Europeans, 89% allergists) reported on approximately 45,000 patients undergoing AIT with any of these conditions. Major problems were infrequent, occurring more frequently in patients with asthma (9.9%) and with previous anaphylaxis from AIT (9.5%). Regarding opinions, experienced physicians scored a significantly lower mean for all conditions than non-experienced physicians for all routes.ConclusionMajor problems were infrequent and experienced physicians were less likely to be restrictive in the use of AIT. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
